Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 rearrange |
| Therapy | Larotrectinib |
| Indication/Tumor Type | colon adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 rearrange | colon adenocarcinoma | predicted - sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, adjuvant Vitrakvi (Larotrectinib) treatment resulted in decrease in the metastases and RECIST stabilization with a progression-free survival of 21 months in a patient with metastatic colon adenocarcinoma harboring an NTRK1 rearrangement who had comorbidities contraindicating the use of chemotherapy (PMID: 41571604). | 41571604 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41571604) | Larotrectinib in Adjuvant and First-Line Treatment for Metastatic NTRK Fusion Colon Cancer. | Full reference... |